<DOC>
	<DOCNO>NCT01227889</DOCNO>
	<brief_summary>BRF113683 Phase III , randomize , open-label study compare efficacy , safety , tolerability GSK2118436 dacarbazine ( DTIC ) , subject BRAF mutant advance ( Stage III ) metastatic ( Stage IV ) melanoma . Subjects randomize receive 150 mg GSK2118436 twice daily 1000 mg/m2 DTIC every 3 week continue treatment disease progression , death , unacceptable adverse event . Subjects progress DTIC allow crossover optional extension arm study receive GSK2118436 .</brief_summary>
	<brief_title>A Study Comparing GSK2118436 Dacarbazine ( DTIC ) Previously Untreated Subjects With BRAF Mutation Positive Advanced ( Stage III ) Metastatic ( Stage IV ) Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Dabrafenib</mesh_term>
	<criteria>Adults least 18 year age Has advance ( unresectable Stage III ) metastatic ( Stage IV ) melanoma BRAF mutation positive ( V600E ) Is treatment naive advance ( unresectable ) metastatic melanoma , exception Interleukin 2 ( IL2 ) allow . Has measurable disease accord RECIST 1.1 criterion . Women childbearing potential must negative pregnancy test within 14 day prior first dose study treatment . Women reproductive potential must willing practice acceptable method birth control study 4 week last dose study medication . Men reproductive potential must willing practice acceptable method birth control study 16 week last dose study medication . Must adequate organ function . Must Eastern Cooperative Oncology Group ( ECOG ) Performance Status 01 . Currently receive cancer therapy ( chemotherapy , radiation therapy , immunotherapy , biologic therapy surgery ) . Evidence active central nervous system ( CNS ) disease . Previous treatment metastatic melanoma , include treatment BRAF MEK inhibitor . A history malignancy . Subjects diseasefree 5 year subject history complete resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . History Human Immunodeficiency Virus ( HIV ) infection . Certain cardiac abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Metastatic melanoma</keyword>
	<keyword>melanoma</keyword>
	<keyword>BRAF mutant</keyword>
	<keyword>Advanced melanoma</keyword>
</DOC>